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ABSTRACT  
The GTPase RhoA is a major player in 
many different regulatory pathways. 
RhoA catalyzes GTP hydrolysis, and its 
catalysis is accelerated when RhoA 
forms heterodimers with proteins of the 
guanine nucleotide exchange factor 
(GEF) family. Neuroepithelial cell 
transforming 1 (Net1) is a RhoA-
interacting GEF implicated in cancer, 
but the structural features supporting 
the RhoA/Net1 interaction are 
unknown. Taking advantage of a simple 
production and purification process, 
here we solved the structure of a 
RhoA/Net1 heterodimer with X-ray 
crystallography at 2 Å resolution. Using 
a panel of several techniques, including 
molecular dynamics simulations, we 
characterized the RhoA/Net1 interface. 
Moreover, deploying an extremely 
simple peptide-based scanning 
approach, we found that short peptides 
(penta- to nona-peptides) derived from 
the protein–protein interaction region 
of RhoA could disrupt the RhoA/Net1 
interaction and thereby diminish the 
rate of nucleotide exchange. The most 
inhibitory peptide, EVKHF, spanning 
residues 102–106 in the RhoA sequence, 
displayed an IC50 of ~100 μM, without 
further modifications. The peptides 
identified here could be useful in 
further investigations of the RhoA/Net1 
interaction region. We propose that our 
structural and functional insights might 
inform chemical approaches for 
transforming the pentapeptide into an 
optimized pseudopeptide that 
antagonizes Net1-mediated RhoA 
activation with therapeutic anticancer 
potential. Rho GTPases control many 
aspects of cell behavior, such as 
cytoskeleton organization, cell-cycle 
progression, and gene transcription (1, 2). 
The dysregulation of Rho proteins 
contributes to  tumorigenesis, metastasis 
(3), hypertension (4, 5), diabetes (6, 7), 
inflammation (8), neuroplasticity (9), and 
cancer (3). Thus, targeting Rho GTPase 
signaling pathways has emerged as a 
promising therapeutic strategy (10, 11).  
In human, 22 genes encode Rho GTPase 
family members. Three members, RhoA, 
Cdc42, and Rac1, are the best 
characterized, and they illustrate the key 
functions of the family (12–15). GTPases 
are molecular switches that cycle between 
the active GTP-bound state and, after GTP 
hydrolysis, the inactive GDP-bound state. 
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In the active state, they recognize target 
proteins and induce cellular responses. 
Two classes of proteins are mainly 
involved in Rho regulation. One class 
comprises GTPase-activating proteins 
(GAPs), which suppress Rho signaling by 
enhancing Rho GTPase activity. The other 
class comprises guanine nucleotide-
exchange factors (GEFs), which promote 
Rho activity by catalyzing the exchange of 
GDP for GTP (16).  
Neuroepithelial transforming gene 1 
(Net1) is a GEF specific for RhoA (17) 
and RhoB (18). Net1 is a protein of 596 
amino acids, with two tandem domains, 
one with Dbl Homology (DH) and the 
other with Pleckstrin Homology (PH), 
which are flanked by amino-terminal and 
carboxyl-terminal extensions. The DH-PH 
domain, present in most GEFs, provides 
the minimal structural unit required to 
catalyze the nucleotide exchange reaction 
in vivo. Net1 shuttles between the nucleus 
and the plasma membrane in response to 
cell-motility stimuli. Furthermore, Net1 is 
overexpressed in a number of human 
cancers, particularly gastric adenocarci-
noma (19, 20). Through RhoA activation, 
Net1 stimulates cell motility, invasion, and 
cell spreading in response to a variety of 
ligands. The cytoskeletal rearrangements 
driven by Net1 comprise a key 
pathological mechanism in gastric tumor 
cell migration and extracellular matrix 
invasion (21, 19). Elevated Net1 
expression levels were shown to correlate 
with the progression of tumors, such as 
hepatocellular carcinoma (22) and lung 
cancers (23).  
The unique role of Net1 in tumor cell 
migration through its interaction with 
RhoA has focused interest on the 
RhoA/Net1 interface as a potential target 
for anti-cancer drugs. Previously, drug 
discovery campaigns attempted to target 
the structurally conserved interface 
between GEFs and RhoA. However, due 
to the limited binding specificity of Rhos 
and GEFs, those approaches have led to 
molecules with severe selectivity issues 
(24). From the purely molecular point of 
view, a few key papers have described the 
relationship between RhoA and GEF 11 or 
GEF 12 (25–28), but little is known 
regarding the interface between RhoA and 
Net1.  
Therefore, we aimed to gain more 
structural information, both on the 
RhoA/Net1 interface and on the complex. 
In the present work, we solved the crystal 
structure of the Net1/RhoA complex with 
X-ray crystallography. Then, with 
molecular modeling and enzymatic assays, 
we identified the residues that contributed 
most of the energy required to form the 
Net1-PH/RhoA interaction. Based on these 
calculations, we determined the molecular 
recognition process. Finally, we designed 
small peptides that could inhibit the 
guanine exchange activity by disrupting 
the Net1-PH/RhoA interface.  
RESULTS & DISCUSSION 
Purification of the Net1/RhoA complex. 
Initially, we purified the Net1
DHPH
 domain, 
which comprised residues 157-494 and a 
hexahistidine (His6) plus a TEV tag at the 
N-terminus. This protein was expressed 
well, and it could be purified in two 
chromatography steps (Ni NTA affinity 
and gel filtration). However, it did not 
show any nucleotide exchange enhancing 
activity. Hence, we extended the C-
terminus to residue 501 (157-501) and 
added a C-terminal His6 tag, which 
restored some GEF activity. Then, we 
altered the N-terminus to start at either 
residue 149 or 170. These final constructs 
exhibited higher GEF activity. We used 
149-501 with a His6 C-terminal tag for 
crystallography. RhoA was prepared as 
described previously (25). These 
recombinant proteins were mixed, 
dialysed, and further purified to yield a 
fair amount of protein amenable to 
crystallography grade material (Figure 1). 
The quality of the preparation was a key 
factor in the next steps of this study. 
Indeed, although not unique (25, 26, 29), 
purifications of this type are not common. 
Overall structure of the Net1
DHPH
/RhoA 
complex. The asymmetric unit had two 
heterodimers of Net1
DHPH
/RhoA. The 
heterodimers were identical as indicated 
by the low RMSD value (0.4 Å or 0.45 Å, 
with RhoA or Net1 as references, 
respectively). Net1 contained the DH and 
PH domains. The DH domain was an 
oblong helical bundle; it facilitates 
nucleotide exchange by forming a stable 
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complex with the nucleotide-free 
conformation of the RhoA GTPase. The 
PH domain was a flattened, 7-standed, B-
barrel, capped with a characteristic C-
terminal -helix (C). The broad picture 
is like what has been described for other 
RhoGEF complexes with a RhoA (30), 
devoid of nucleotide and with a large 
interface (Figure 2) 
In our structure, RhoA was clamped 
between the DH and PH domains of Net1. 
This conformation was cation- and 
nucleotide-free, with switch I removed 
from the nucleotide-binding site and 
switch II pulled towards the nucleotide-
binding site. This conformation was 
similar to those previously reported for 
RhoA/GEF complexes, where the 
interaction with the DH/PH domains 
stabilized the nucleotide-free form of 
RhoA by altering the structures of the two 
switches.  
A superposition of this RhoA with the 
structure of RhoA in complex with a 
nucleotide indicated a likely binding site 
for the nucleotide in the RhoA/Net1 
complex. Indeed, we reasoned that the 
nucleotide was likely to bind to the active 
site through an extensive network of 
hydrogen bonds, including residues G17, 
K18, and T19, which could interact with 
the pyrophosphate group. Additionally, 
residues K118, D120, A161, and K162 
could interact with the guanosine moiety 
(Figure 3). The cation-π interaction 
between the guanine and K118 is 
conserved among RhoA structures solved 
in presence of nucleotide. In our structure, 
the conformation of the RhoA active site 
was nearly identical to that described 
previously, for RhoGEF12 (RhoGEF12; 
RMSD 1.1 Å with RhoA: PDB code 
1X86) (26). In particular, the orientation 
of the loop near the G14 residue, critical 
for GTP binding, was similar in these two 
structures; the lateral chain pointed 
towards the nucleotide-binding site, and 
thus, preventing nucleotide binding.  The 
160-165 loop was significantly 
reorganized, which allowed the formation 
of hydrogen bonds between the guanine 
and A161 and K162. This conformation 
was observed previously in the structure of 
Rho/GEF11 (PDB code 1XCG) (25).  
Comparison of the Net1
DHPH
 (4XH9) and 
Net1
DH
 (3EO2) structures. The crystal 
structure of the DH domain was 
previously solved with a resolution of 2.6 
Å (PDB code 3EO2). The RMSD analysis 
calculated for the main chains of Net1
DHPH
 
(PDB code 4XH9) and Net1
DH 
(PDB code 
3EO2) pointed out that residues 280-310 
were severely deviated in Net1
DH
 (Figure 
4A). Upon RhoA binding, the N-terminal 
domain of NET1
DHPH
 was shifted by ~40 
degrees compared to Net1
DH 
(Figure 4B); 
this shift prevented steric clashes between 
residues S306 and D309 on Net1 and W58 
on RhoA (Figure 4C). A consequence of 
this reorganization was the displacement 
of the 284-295 alpha helix, induced by the 
H-bond formed between W305 of 
Net1
DHPH 
and L72 of RhoA. 
The DH/RhoA interface. All the 
interactions between Net1
DHPH
 and RhoA 
were conserved in the two complexes of 
the asymmetric unit. Twelve amino acids 
in RhoA, distributed between R5 and S73, 
were involved in polar interactions with 
DH. Moreover, E40, D45, and E76 in 
RhoA established salt bridges with K317, 
K301 and K274 in DH (Figures 5A & B). 
Residues V38, V43, W58, and Y66 in 
RhoA and L321, L302, W305, and L350 
in DH were involved in hydrophobic 
interactions (within 4 Å). With the PISA 
server, we found the closest homologues 
available in the RCSB data bank, based on 
interface homology. The most significant 
homologues for which a similar interface 
was previously described were 
RhoA/GEF12 (PDB code 1X86) (26) and  
RhoA/GEF11 (PDB code 1XCG) (25). 
Despite a rather low sequence homology 
between these two RhoGEF proteins, 
many of the residues involved in the 
interactions with RhoA were conserved. 
There are nevertheless original contacts in 
the case of Net1 as shown in Table 1.  
The PH/RhoA interface. X-ray 
crystallography models were 
supplemented with molecular dynamics 
simulations to provide insight into the 
dynamic properties and conformational 
changes of the RhoA/Net1 complex. We 
found that the presence of RhoA strongly 
influenced the conformational dynamics of 
the Net1 PH domain (Figures 6A, B). In 
complex with RhoA, the N-terminal 
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domain of the α6-helix of Net1 PH 
remained stable, in a position similar to 
that observed in the crystal structure 
(RMSD=1Å), and the PH/DH domain 
angle remained constant at approximately 
125º (Figure 6A). On the other hand, in 
the RhoA-free system, Net1 samples 
displayed multiple conformal states 
(Figure 6B). The absence of the Net1-
RhoA interaction increased the flexibility 
of α6-helix, which altered the position of 
the PH domain.  
No RhoA guanine nucleotide exchange 
could be detected with the isolated DH 
domain in the in vitro exchange assay 
(Figure 7). Thus, we concluded that the 
presence of the PH domain was critical to 
the activity of Net1, and that it must be 
stabilized in the interaction with RhoA.  
In the Rho/GEF11 and Rho/GEF12 crystal 
structures, the binding of PH to RhoA is 
mediated by two forces. One is a hydrogen 
bond between E97 in RhoA and 
S1118/S1065 in PH; the other is a salt 
bridge formed by R68 in RhoA with either 
E1023 or E969 in PH (Figure 8A). This 
binding mode was not observed in the 
Net1
DHPH
/RhoA structure, which suggested 
that the Net1 PH domain must be 
stabilized in a unique way. We found that, 
in the Net1
DHPH
/RhoA crystal structure, the 
H105 residue in RhoA bridged the water 
molecule, WATER1, which was further 
stabilized by E392, W492, and H488 in 
the Net1 PH domain. RhoA H105 also 
interacted with the H390 amide group, 
either directly or with the mediation of 
water (WATER2). The imidazole ring 
formed both a salt bridge with E361 in the 
DH domain (known as the DHPH 
intrachain interaction) and a π-π 
interaction with the Y365 phenyl ring 
(Figure 8B). The existence of this unique 
mode of interaction was supported by low 
values of the b factors, calculated after 
isotropic refinement, and the RMSD of the 
residues/waters measured in the molecular 
dynamics simulations (Table 2). 
Net1
PH
 was later purified to investigate the 
in vitro formation of the Net1
PH
/RhoA 
heterodimer. First, the folding of Net1
PH
 
was confirmed with 1H NMR. The NH 
signals in the range of ~8.00 to 9.6 PPM 
and signals down to -0.5 PPM matched the 
aromatic and the aliphatic regions of the 
spectrum (Figure 9A). This result 
indicated the presence of folding in the 
structure. The abundance of signals in the 
region of 8.5 PPM may indicate the 
presence of unfolded regions in the PH 
domain. The interaction between Net1
PH 
and RhoA was analyzed by gel filtration 
chromatography (Figure 9B) and SDS-
PAGE electrophoresis (Figure 9C). 
Despite different ratios of Net1
PH
 to RhoA 
(1:1 and 2:1), we observed no dimer 
formation, as indicated by the lack of 
Net1
PH
 in the eluted fractions of high 
molecular weights. Consequently, we 
concluded that the binding of Net1
PH
 to 
RhoA was most likely induced by the 
binding of Net1-DH to RhoA. 
Alternatively, one might consider that the 
interaction of Net1PH (i.e. without its DH 
domain) with RhoA is too weak to have 
been detected by the methods used.  
Targeting the PH/RhoA interface with 
small peptides. The previous finding that 
Net1 played a role in metastatic processes 
served as an incentive to target it. Early 
attempts to target a specific GEF 
DH/RhoA interface led to non-specific 
inhibition, due to the fact that the 
DH/RhoA interface is highly conserved 
among GEFs. Therefore, we reasoned that 
the unique Net1-PH/RhoA interface may 
provide a selective target for altering the 
cellular effects of Net1. However, 
targeting protein–protein interactions has 
long been considered highly challenging, 
due to their large, dynamic interfaces. To 
address these challenges, we employed 
computational approaches to design small 
peptides that mimicked the key Net1-
RhoA interface interactions.  
We used a decomposition approach that 
combined molecular mechanics energies 
with the generalized Born and surface area 
continuum solvation (MM-GBSA) to 
identify the residues that made the most 
important energetic contributions to the 
formation of the PH domain/RhoA 
complex (Figure 10A, B). Residues D485 
to Q491 in Net1 contributed significantly 
to the binding free energy of the complex. 
This segment established multiple 
interactions with residues 100 to 106 in 
RhoA. In particular, D485 and H488 
(Net1) formed several hydrogen bonds and 
salt bridges with K104 and H105 (RhoA). 
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As a result of this analysis, we identified 
potential hotspots involved in the binding 
between Net1 and RhoA. This information 
allowed us to initiate competition assays 
with peptides derived from the loops of 
contact in RhoA. Peptides that mimicked 
potential hot-spots in segment 96 to 106 of 
RhoA were designed to perturb the 
Net1
DHPH
/RhoA interface. We monitored 
the inhibition of guanine nucleotide 
exchange to identify hot-spots that 
affected function (Figure 11A, B). 
Competitive assays performed with 
peptide 96-102 that formed the RhoA 
“hydrophobic pocket” showed no 
inhibition efficiency in the molecular 
dynamics analysis. In contrast, a short 
peptide that spanned amino acids 102 to 
106 exhibited an IC50 of 116.5 ± 6.3 µM 
(Figure 11 C). Longer peptides (96-106 or 
100-109) display poor inhibition effect, 
suggesting folding/aggregation issues. 
Finally, no inhibition of Net1 was 
measured when peptide 100-105, devoid 
of the phenyalanine F106, was used. 
This finding indicated that the stabilization 
of PH on RhoA was mediated by a limited 
number of residues in the 102-106 
segment of RhoA. Next, we estimated the 
selectivity of peptide 102-106 inhibition 
by measuring its effect on the guanine 
exchange activity of the two closest 
homologues of Net1: GEF3 and GEF12 
(16) (Figure 12A & B). We found that 0.5 
mM of peptide 102-106 did not 
significantly inhibit GEF3 and GEF12 
activities. The inefficient effect of peptide 
102-106 on GEF12 could be explained by 
the difference in the PH/RhoA interfaces 
observed in the crystal structures. The 
inability of peptide 102-106 to inhibit 
GEF3 was unexpected, because the Net1 
and GEF3 sequences varied by only a 
single amino acid in this region where 
both proteins seem to interact (His488 in 
Net1 vs. Asn436 in GEF3; Figure 13). 
This finding suggests that His488 is a 
driving residue for the peptide recognition 
and the selectivity process. To confirm this 
hypothesis, the activities of mutated Net1 
(H488A and H488N) and GEF3 (N436H) 
were measured in the presence of the 
peptide 102-106. Mutation of H488N or of 
H488A made NET1 insensitive to the 
peptide 102-106 whereas sensitivity to the 
peptide was partially restored for the 
mutated GEF3 N436H (Figure 14). These 
results confirmed that i) the peptide 
mimics the binding of RhoA to Net1 PH 
domain and that ii), the selectivity is 
driven by the residue H488.  
 
To summarize, a hot-spot has been 
identified at the Net1/RhoA interface and 
structure-activity analysis of key residues 
of the peptide 102-106 (EVKHF) led to 
the identification of three functional 
groups that will help to generate 
pharmacophore models representing all 
necessary functional properties in the 
appropriate spacing and 3-D orientation 
required to facilitate compound optimization:  
a scaffold (made by the H105 imidazole 
ring), a hydrophobic pocket suitable to 
improve the lipophilic properties during 
the lead generation (F106 phenyl ring) as 
well as an array to develop the compound 
selectivity (toward the targeting of Net1 
H488).  
As a conclusion, the search for new 
approaches for identifying molecules for 
fighting cancer remains dramatically 
important. Gaining a better understanding 
of the molecular nature of relationships 
that regulate protein-protein interactions 
will facilitate achieving this goal. 
However, when the target of interest is 
neither an enzyme nor a receptor, the 
nature of the protein-protein interaction 
that regulates the complex is often a flat 
surface, where hotspots are either difficult 
to find or simply do not exist (31). An 
abundance of technologies have been 
described in the last few years, which have 
facilitated the achievement of this difficult 
task. In some cases, those efforts have 
provided patients with less toxic, more 
specific, tolerable compounds, and 
ultimately drugs (32). Consequently, it is 
recommended that three paradigms should 
be revisited: (i) finding specific proteins 
involved in subclasses of diseases; (ii) 
improving the descriptions, and thus, the 
understanding of protein-protein 
interactions at the molecular level  (33, 
34); and (iii) demonstrating that even ‘flat’ 
surfaces can be druggable, particularly 
with peptides or macrocycles, which are 
good starting points for that type of 
discovery program (35). Here, we used a 
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simple biochemical approach to produce 
the two partners of the Net1/RhoA 
complex. This study was the first to solve 
their co-crystal structure, and thus, the 
structure of this type of complex. From 
there, we used modern molecular 
dynamics tools to describe the behavior of 
the complex and the nature of the interface 
between these proteins. Then, we designed 
short peptide sequences and showed that  
small sequences could interfere with the 
interaction between RhoA and Net1, 
which led to the impairment of RhoA 
catalytic activity. Although much remains 
to be undertaken before reaching patients, 
these results exemplified the technical and 
strategic avenues that can lead to progress. 
 
EXPERIMENTAL PROCEDURES. 
Reagents and peptides. All reagents used 
in the present work were of analytical 
grade or better. Peptides were custom-
synthesized by Genepep (St Jean de 
Vedas, France). In brief, they were 
synthesized with the solid-phase synthesis 
method, cleaved off the resin, purified, and 
thoroughly analyzed with HPLC and mass 
spectrometry. Peptide purity was 
systematically higher than 98%, judged by 
both techniques. 
Plasmids and recombinant proteins. Two 
plasmids were constructed, one carried the 
sequence encoding human RhoA (residues 
2-180), with a F25N mutation, and the 
other carried the sequence encoding 
human Net1 (residues 149-501). Both 
constructs were cloned into pET28 and 
expressed in Escherichia coli BL21 RIL 
(DE3) cells as His6-tagged proteins (an N-
terminal tag, plus a TEV cleavage site for 
RhoA, and a C-terminal tag for Net1). The 
cells were grown overnight at 17°C in 
auto-inducing media (36). Cells were 
harvested by centrifugation and 
resuspended in lysis buffer (50 mM Tris 
pH8, 250 mM NaCl, 10% (w/v) glycerol, 
10 mM MgCl2, 1 mM PMSF, 20 mM 
MgSO4) in the presence of  10 mg DNAse 
and 250 mg/L lysozyme per liter of buffer. 
During the isolation of RhoA, all buffers, 
from lysis to the final purification step, 
were supplemented with 50 µM GDP. The 
proteins were purified independently, but 
in a similar fashion, on His Trap FF crude 
columns (5 mL). After loading the sample, 
the column was washed with 20 volumes 
of wash buffer (50 Tris mM pH8, 250 mM 
NaCl, 10 mM MgCl2, 50 µM GDP, 10% 
(w/v) glycerol). The protein was eluted 
with 50 mM Tris pH8, 250 mM NaCl, 10 
mM MgCl2, 10% (w/v) glycerol, and 250 
mM imidazole.  
For RhoA purification, the protein was 
then desalted in 20 mM Tris pH8, 250 mM 
NaCl, 2 mM DTT, 5% glycerol, 1 mM 
MgCl2, 50 µM GDP, and cleaved 
overnight with TEV protease at 4°C. The 
sample was then passed through a His trap 
FF column equilibrated with cleavage 
buffer. Next, the sample was concentrated 
to 5 mg/mL. The protein was purified with 
gel filtration chromatography (Superdex 
200 26/60, GE Healthcare) in 20 mM Tris 
pH8, 10 mM HCl, 250 mM NaCl, 2 mM 
DTT, 5% glycerol, 1 mM MgCl2, and 50 
µM GDP.  
For Net1 isolation, after histrap FF 
purification step, Net1
DHPH
 was directly 
purified with gel filtration chromatography 
(Superdex 200 26/60, GE Healthcare) in 
20 mM Hepes pH7.5, 150 mM NaCl, 5% 
(w/v) glycerol, 2 mM DTT.  
The Net-Rho complex was produced by 
incubating GDP-loaded RhoA with 
Net1
DHPH
 at a molar ratio of 2:1 for 10 
min, followed by overnight dialysis in 20 
mM Tris pH7.1, 150 mM NaCl, 5 mM 
EDTA, 1 mM TCEP. A final gel filtration 
step (Superdex 75 26/60, GE Healthcare), 
in 20 mM Tris pH7.2, 150 mM NaCl, 1 
mM TCEP (Figure 1), was used to isolate 
the RhoA-Net1
DHPH
 complex from free 
RhoA. The complex was concentrated to 
12 mg/mL, and this sample was used for 
crystallization experiments. 
Protein purification. Net1 (residues 149-
501) H488N, Net1 (residues 149-501) 
H488A and DH domain (residues 149 to 
370). The Net1 sequence encoding 
residues 149-370 was cloned into the 
pET15 plasmid and expressed in E. coli 
BL21 (DE3) cells as a His6-tagged protein 
(N-terminal tag with a TEV cleavage site).  
H488A or H488N mutation was inserted 
following the QuikChange II Site-Directed 
Mutagenesis (Agilent technologies) 
procedure. 
Cells were grown in auto-inducing media 
at 20°C. Net1_DH,  Net1 H488N and Net1 
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H488A were purified with the procedure 
described above for Net1-149-501. 
Protein purification. PH domain (residues 
358 to 501). The Net1 sequence encoding 
residues 358-501 was cloned into the 
pET15 plasmid and expressed in E. coli 
BL21 (DE3) cells as a His6-Maltose 
Binding Protein (MBP) tagged protein (N-
terminal tag with a TEV cleavage site). 
Cells were grown in LB media at 17°C 
after induction with 0.1 mM isopropyl β-
D-1-thiogalactopyranoside (IPTG). Harv-
ested cells were re-suspended in a lysis 
buffer of 50 mM Tris, 200 mM NaCl, 10% 
glycerol, 1 mM TCEP, pH7.5, 
supplemented with DNAse and anti-
proteases. Cells were lysed at 30 psi with a 
cell disruptor. Net1_358-501 was initially 
purified with affinity chromatography in 
50 mM Tris, 200 mM NaCl, 10% glycerol, 
1 mM TCEP, pH7.5 500 mM imidazole. 
Then, it was purified with the procedure 
described above for Net1_149-501. 
Fractions of interest were further purified 
with gel filtration chromatography on a 
Superdex 75 26/60, pre-equilibrated with 
50 mM Tris, 200 mM NaCl, 10% glycerol, 
1 mM TCEP pH7.5. Pure fractions were 
pooled and incubated with 1/20 TEV 
overnight at 4°C under slow agitation. The 
mixture was diluted (4) in Hepes 50 mM, 
10% glycerol, 1 mM TCEP pH 7.3, to 
achieve a final concentration of 50 mM 
NaCl. The sample was then loaded on a Hi 
Trap SP column (5 mL) that had been pre-
equilibrated in 50 mM Hepes, 50 mM 
NaCl, 10% glycerol, 1 mM TCEP pH 7.3 
at a flow rate of 6 mL/min. Flow-through 
fractions were saved. Elution was 
performed with a salt gradient (50 to 500 
mM) in 35 min at a flow rate of 2 mL/min. 
Protein purification. ARHGEF3 (residues 
S94 to E449) and ARHGEF3 (residues 
S94 to E449) N436H. The gene encoding 
the DH-PH domain (S94-E449) of H. 
sapien GEF3 was cloned into the pET15 
vector as a His6-tagged protein (C-terminal 
tag) and expressed in E. coli BL21 (DE3) 
cells in auto-induction media at 17°C. 
N436H mutation was inserted following 
the QuikChange II Site-Directed 
Mutagenesis (Agilent technologies) 
procedure.  ARHGEF3 (WT and N436H) 
were purified with the procedure described 
above for Net1-149-501. 
Protein purification. ARHGEF12 
(residues N768 to S1138, with a Y973F 
mutation). The gene encoding the DH-PH 
domain (N768-S1138) of H. sapien 
GEF12 was cloned into the pET15 vector 
with both an MBP-tag (N-terminal tag 
with TEV) and a His6-tag (C-terminal tag). 
The protein was expressed in E. coli BL21 
RIL (DE3) cells in auto-induction media at 
17°C. ARHGEF12 was initially purified 
with affinity chromatography, according to 
the procedure described above for 
Net1_149-501. Then, samples containing 
ARHGEF12 were pooled and immediately 
dialysed overnight at 4°C in the presence 
of TEV protease (1/20) against 50 mM 
Tris, 200 mM NaCl, 10% glycerol, 1 mM 
TCEP pH7.5. Samples were then passed 
through a HisTrap HP (5 mL) Ni-NTA 
column and eluted with a gradient of 5 to 
50% B (Buffer supplemented with 500 
mM imidazole) in 50 min at a flow rate of 
2 mL/min. Fractions of interest were 
applied to a Superdex 75 26/60 column 
(GE Healthcare) that had been pre-
equilibrated with 50 mM Tris, 200 mM 
NaCl, 10% glycerol, 1 mM TCEP, pH 7.5. 
1
H-NMR analysis of Net1
PH
 domain 
(residues 358 to 501). A 200 μL volume of 
protein was brought to a concentration of 
1.8 mg/mL (104.8 μM) in 20 mM Tris, 
200 mM NaCl, 10% glycerol, 1 mM TCEP 
pH 7.5. This solution was mixed with 20 
μL D2O (Cambridge Isotopes Laboratory) 
and placed in a 3 mm NMR tube (Wilmad 
307-PP-7). The NMR experiment was 
performed at 20°C on a Bruker AVANCE 
III HD spectrometer equipped with a QCI-
F cryoprobe, operating at 500.13 MHz. 
The spectrum was analyzed with the 
TopSpin 3.2 program. Protein folding was 
evaluated, based on the presence of a wide 
range of NH signals in the region of 8.0 to 
9.6 ppm and aliphatic signals in the region 
of -0.6 to 0.5 ppm. 
Analysis of the dispersion of the NMR 
signals in the regions of the methyl 
protons (0.5 to 1.5 ppm), -alpha-protons 
(3.5– 6 ppm), and amide protons (6–10 
ppm) confirmed the folding of the Net1
PH 
purified protein (37).  
Analytic gel filtration chromatography of 
the Net
PH
 domain/RhoA complex. 
Retention profiles of Net1
PH 
in presence or 
absence of RhoA were analyzed with gel 
 at U
N
IV
ERSITY
 O
F D
U
N
D
EE on M
ay 3, 2018
http://w
w
w
.jbc.org/
D
ow
nloaded from
 
Druggable rhoA/Net1 interface 
8 
 
filtration chromatography. As controls, 7 
nmoles of Net1
PH
 and 7 nmoles of RhoA 
were loaded on a Superdex 75 10/300 GL 
that had been pre-equilibrated in 20 mM 
Tris, 100 mM NaCl, 5% glycerol,  0.5 mM 
TCEP pH7.5. To analyze the complex, 7 
nmoles of Net1
PH
 and 7 nmoles of RhoA 
were preincubated for 2 h at 4°C before 
the gel filtration analysis. A ratio of 2:1 
was also analyzed with the same 
procedure, by mixing 20 nmoles of Net1
PH
 
with 10 nmoles of RhoA. 
Crystallization and structure 
determination. The RhoA-Net1
DHPH
 
complex was crystallized at 20°C with the 
hanging drop vapor diffusion method. 
Crystals appeared overnight in drops 
composed of 1 µL protein solution mixed 
with 1 µL of the reservoir solution, which 
contained 0.1 M Bis-tris propane pH 7.5, 
20% PEG3350, and 0.2 M tripotassium 
phosphate. Crystals were flash-frozen in 
the reservoir solution supplemented with 
15% glycerol. Data were collected at 100 
K (after annealing) from the synchrotron 
radiation beamline, ID23 (ESRF, 
Grenoble, France). Data were processed 
with the XDS program (38) and scaled 
with the SCALA program in the CCP4 
suite (39). The initial phase information 
was obtained by performing molecular 
replacement with Phaser, from the CCP4 
suite, and a model built from our own 
crystal structure of the apo Net1
DH
 domain 
(data not shown) combined with RhoA. 
The initial densities were improved further 
by applying solvent flattening and 
histogram matching with RESOLVE from 
the Phenix suite (40, 41). Then, the PH 
domain of Rho GEF 3 (PDB code 2Z0Q) 
was density-fitted with Phaser to improve 
the density map of the DH domain. The 
model was finally improved by applying 
iterative cycles of model building and 
refinement with COOT (42) and Refine 
(Phenix suite) (40, 41). Here, we present 
the data measurements (Table 3) and 
model refinement statistics (Table 4). 
Coordinate files and associated 
experimental data have been deposited in 
the Protein Data Bank (PDB); accession 
code 4XH9. 
Molecular modeling and simulations. 
Molecular modeling and simulation 
protocols were used to study, in atomic 
detail, the structural stability of Net1. The 
following systems were simulated: i) Net1 
and ii) the Net1/RhoA complex. Each 
system was built with a template of our 
crystal structure of Net1 in complex with 
RhoA. Missing loops were modeled with 
the SWISS-MODEL web interface (43). 
Hydrogen atoms were added to the protein 
with the web-based H++ server, which 
assigned protonation states to all titratable 
residues at the chosen pH of 7.0 (44). Each 
system was immersed in a TIP3P water 
box (45) and neutralized with the 
appropriate number of counter ions (46).  
Molecular dynamics simulation protocols. 
Standard molecular dynamics simulations 
were performed with the pmemd.cuda 
module provided in the AMBER14 suite 
of programs (47), with the ff14SB force 
field (48). The cut-off distance for the 
non-bonded interactions was 10Å, and 
periodic boundary conditions were 
applied. Long-range electrostatic 
interactions were treated with the particle 
mesh Ewald method (49).  The SHAKE 
algorithm was applied to all bonds 
involving hydrogens (50), and an 
integration step of 2-fs was used 
throughout. Each system was studied with 
two 100-ns replicas of unrestrained 
molecular dynamics simulations, run at a 
constant temperature (300 K) and pressure 
(1 atm) with the weak-coupling algorithm 
(51).  
Analysis methods. Three-dimensional 
structures were inspected with the 
computer graphics programs, PyMOL (52) 
and VMD (53). Interatomic distances, 
angles, and RMSDs were monitored with 
the “cpptraj” module in AmberTools15 
(47). The last 80 ns of the molecular 
dynamics trajectories of each system were 
used to construct two-dimensional 
normalized density maps. The maps 
showed the conformational states of Net1 
in the presence and absence of RhoA, 
based on two selected collective variables. 
The first variable, ‘x’, corresponded to the 
RMSD of the backbone atoms of residues 
357-368. It was calculated after aligning 
only residues 158-354 of the DH domain; 
the crystal structure of Net1 in complex 
with RhoA (PDB entry 4XH9) was used 
as reference. The second variable, ‘y’, 
corresponded to the DH-PH angle; i.e., the 
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angle between the alpha carbons of 
residues Q337, L355 (DH domain), and 
I496 (PH domain). We identified the 
dominant residues that contributed energy 
to the formation of the Net1-PH/RhoA 
complex by calculating the binding free 
energies of the complex with the MM-
GBSA per-residue decomposition 
analysis, as implemented in the 
MMPBSA.py software (54). 
Guanine nucleotide exchange assay. In 
vitro nucleotide exchange assays measured 
the increase in fluorescence emitted over 
time, upon incorporation of free Mant-
GTP into a GDP-loaded RhoA molecule. 
To analyze the inhibition of the 
GDP/mant-GTP exchange reaction, the 
time course of the change in fluorescence 
was recorded in the presence of increasing 
concentrations of peptides (0.03 to 0.5 
mM). The peptide and 1 μM RhoA were 
mixed at 25°C in 100 µL of 20 mM Hepes 
pH 7, 150 mM NaCl, 1 mM MgCl2, 1 µM 
mant-GTP. The reaction was initiated with 
the addition of 1 µM Net1 or 10 μM 
ARHGEF3 or 0.05 μM ARHGEF12. 
Total fluorescence intensities were 
measured with a Varian Cary Eclipse 
Fluorescence Spectrophotometer (λex = 
360 nm, λem = 440 nm).  
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Table 1: Analysis of the interactions between RhoA and the DH domains of Net1, 
RhoGEF11 and RhoGEF12. 
The distance corresponds to the distance measured during the 100-ns run in the molecular 
dynamics (MD) simulations of the interaction between Net1 and RhoA. Residues in italic are 
not homologous in the superposed structures of Net1, RhoGEF11, and RhoGEF12. 
 
RhoA 
 
Net1 
(4XH9) 
RhoGEF11 
(1XCG) 
RhoGEF12 
(1X86) 
Distance 
(Å) 
Distance measured  
in MD (Å) 
Hydrogen bonds  
R5 Q291 R868/D873 R923 2.7 4.5 (± 1.0) 
T37 E181 E741 E794 2.8 2.8 (± 0.2) 
V38 E181 E741 E794 3.1 3.3 (± 0.4) 
N41 S306 Q880 Q935 2.9 4.5 (± 1.3) 
D67 N354 N921 N975 3.6 3.6 (± 0.4) 
R68 N354 N921 N975 2.9 3.0 (± 0.2) 
L69 N354 N921 N975 3.1 3.2 (± 0.3) 
E40 S313 S748 - 2.7 5.9 (± 0.9) 
Q63 R312 - - 3.1 3.0 (± 0.3) 
R68 K357 - E982/N983  2.8 3.0 (± 0.5) 
L69 R312 - - 2.9 3.0 (± 0.3) 
L72 W305 - - 3.6 4.2 (± 0.5) 
S73 R312 - - 2.6 3.0 (± 0.3) 
Salt bridges  
E40 K317 R751/R867 R922 3.6 2.9 (± 0.3) 
D45 K301 R868 R923 3.9 5.2 (± 1.9) 
D76 K274 R872 K899 2.9 3.4 (± 1.0) 
 
 at U
N
IV
ERSITY
 O
F D
U
N
D
EE on M
ay 3, 2018
http://w
w
w
.jbc.org/
D
ow
nloaded from
 
Druggable rhoA/Net1 interface 
16 
 
Table 2: Analysis of the interactions between RhoA and the PH domains of Net1  
 
 
 
 
*values represent the AB heterodimer of the asymmetric unit; MD: molecular 
dynamics  
Putative Hbond 
involved 
in the PH/RhoA 
interface 
Distance 
measured in 
4XH9 
Distance 
measured 
in MD 
 
Isotropic refinement B factors* (Å
2
) 
Residue / water 
molecule 
Chain 
WATER1-H488(Nε2) 3.0 3.0 (± 0.2) H488 18 
Net1-PH 
Average 30 
Min 16 
Max 64 
WATER1-E392(O) 2.8 2.8 (± 0.2) 
E392 21 
WATER1-E392(N) 3.3 3.4 (± 0.3) 
WATER1-W492(Nε1) 2.8 3.0 (± 0.2) W492 17 
WATER2-H390(N) 3.0 3.1 (± 0.3) H390 18 
H105(Nε2)-H390(O) 2.9 3.2 (± 0.4) H105 15 
RhoA 
Average 28 
Min 13 
Max 64 
WATER1-H105(Nδ1) 3.4 3.7 (± 0.3) WATER1 16 Waters 
Average 37 
Min 14 
Max 57 WATER2-H105(Nε2) 2.9 3.3 (± 0.4) WATER2 22 
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Table 3 Crystallographic data collection and processing 
Data collection and processing were conducted at the European Synchrotron Radiation 
Facility ESRF (Grenoble, France) on the ID23-1 beamline. 
 
Parameter Value 
  
Wavelength (Å) 0.97 
Temperature (K) 100 
Detector: Pilatus 6M  
Crystal-detector distance (mm)  250 
Rotation range per image (°)  1 
Total rotation range (°)  200 
Exposure time per image (s)  0.5  
Space group P1211 
a; b; c (Å)  54.1; 101.4; 116.2 
α; β; γ (°)  90.0; 94.3; 90.0  
Resolution range (Å) 34.0-2.0 (2.1-2.0) 
No. of unique reflections 83900 
Completeness (%) 96 (90.4) 
Redundancy 3.4 (3.4) 
 [I/σ(I)]  13.9 (3.9) 
Overall B factor from Wilson plot (Å
2
)  26.3  
 
 
Values in parentheses represent the outer shell. 
†estimated by multiplying the conventional Rmerge value by the factor [N/(N − 1)]
1/2
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Table 4: Crystallographic structure solution and refinement  
 
Parameter Value 
Resolution range (Å) 35.0-2.0  
Completeness (%) 99.4  
σ cutoff   2.0 
No. of reflections, working set 83896 
No. of reflections, test set 4194 
Final Rcryst  1.1.1.1.1.1.1 0.18 
Final Rfree  1.1.1.1.1.1.2 0.21 
Cruickshank DPI   
No. of non-H atoms 9206 
 Protein 8269 
 Water 921 
 Total  
RMSDs    
 Bonds (Å) 0.012 
 Angles (°) 1.39 
Average B factors (Å
2
)  35 
 Protein 29 
 Water 78 
Ramachandran plot    
 Most favored (%) 97.2 
 Allowed (%) 2.4 
RMSDs: root mean square deviations 
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Figure Legends 
 
Figure 1: Purification of the Net1
DHPH
/RhoA complex  
(A) Superdex S200 26-60 gel-filtration profile of the Net1
DHPH
/RhoA complex. (B) 
Coomassie-stained SDS-PAGE gel shows the Net1
DHPH
/RhoA complex isolated with 
Superdex S200 chromatography. MW markers.10, 15, 25, 35, 45, 67, 90 kDa; Lane 1: the 
higher band is the Net1/RhoA complex; Lane 2: lower band shows excess unbound RhoA.   
 
Figure 2: Overall crystal structure of RhoA/Net1
DHPH
 complex 
RhoA is shown in orange; switch 1 is in purple and switch 2 is in green (30). The Net1 DH 
domain is in cyan and the Net 1 PH domain is in yellow. 
 
Figure 3: Superposition of the RhoA structure from the Net1
DHPH
/RhoA complex with a 
bound GDP structure suggests the likely binding site for GDP.  
The RhoA (orange, with cyan side-chains) from the Net1
DHPH
/RhoA structure (PBD code 
4XH9) is superposed onto the GDP (purple, with a red pyrophosphate) from the RhoA/GDP 
structure (PDB code 4D0N). 
 
Figure 4: Comparison of Net1
DHPH
 (PDB code 4XH9) and Net1
DH
 (PDB code 3EO2) 
structures. 
(A) Calculated RMSDs for Net1
DHPH
 and Net1
DH
. The main chain deviations calculated with 
PROGRAM are indicated for each residue (circles). (B) Alignment of Net1
DHPH
 (blue/yellow) 
and Net1
DH
 (magenta) structures. RhoA is shown in orange. (C) Close-up view of the 
alignment of Net1
DHPH
 (cyan, with blue side-chains) and Net1
DH
 (magenta, with magenta side-
chains) structures shows that D309 could not be involved in RhoA binding to Net1, due to the 
clash between S306/D309 from Net1 and W58 from RhoA (green). 
 
Figure 5: The DH/RhoA interface 
(A) DH residues (blue) involved in the interface. B) RhoA  residues (magenta) involved in the 
interface. RhoA is shown in orange, DH in cyan. 
 
Figure 6:  Conformational distributions of the DH/PH domains of Net1. Molecular 
dynamics results show the root mean square deviation (RMSD) of the α6 helix (residues 357-
368) on the X-axis (Å), and the DH/PH angle (i.e., the angle between the Cα carbons of 
residues Q337, L355, and I496) on the Y-axis (degrees). Each plot shows representative 
structures of Net1; the α6 and αC helices are shown in cyan and yellow cylinders, 
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respectively. The color scale indicates the number of occurrences per bin normalized to the 
maximum number in a bin (A) Net1 in complex with RhoA; (B) Net1 in the absence of RhoA 
  
Figure 7: Biochemical characterization of GTP/GDP exchange activities for the 
Net1/RhoA complex.  
 
. RhoA exchange activity was measured in the presence of the DHPH segment of Net1 (1 µM, 
dark circles). The GTP/GDP exchange activity of Net1 DH (10 µM) is shown as control 
experiment (half-tone symbols). The experiments were run at least 3 times, independently. A 
representative curve is presented here. 
 
Figure 8: The PH/RhoA interface 
(A) Structural alignment of the PH domains in Net1
DHPH
 (yellow/blue), RhoGEF11 (brown), 
and RhoGEF12 (green). Net1 corresponding residues based on the sequences alignement are 
shown in sticks.  
(B) The Net1 PH/RhoA interface; interactions between side-chains are shown for the Net1 
DH (cyan) and PH domains (yellow) and RhoA (orange).  
 
Figure 9: Net1PH/RhoA heterodimer formation analysis  
(A) NMR data show  the protein complex (200 µL at a concentration of 1.8 mg/mL, 104.8 
μM) in 20 mM Tris, 200 mM NaCl, 10% glycerol, 1 mM TCEP, pH 7.5, mixed with 20 μL 
D2O, and placed in a 3-mm NMR tube. (B) Superdex S75 10/300 gel-filtration profile of 
Net1
PH
 (orange), RhoA (green), and Net1
PH
 pre-incubated with RhoA at a ratio of 1:1 (pink) 
or 2:1 (blue). The eluted fractions (1-7) are indicated with red numbers. The peak observed at 
17 mL corresponds to the GDP present in the RhoA buffer. (C) TGX Stain-free SDS-PAGE 
gel of the elution fractions from the Net1
PH
 RhoA gel-filtration run (ratio 2:1). Lane 1: 
Net1
PH
, fraction 6; Lane 2: RhoA, fraction 4; Lane 3: Molecular weight markers: 10, 15, 20, 
25, 37, 50, 75, 100, 150, 250 kDa; Lanes 4-10. Elution fractions 1-7 from Net1
PH
 RhoA (ratio 
2:1; blue trace in panel A) 
 .  
 
Figure 10: MM-GBSA per residue decomposition analysis of the Net1 PH domain (top) 
and the RhoA (bottom) complex. The total binding free energy contribution is shown for 
each amino acid residue, and those with the highest contributions are highlighted. MM-
GBSA: molecular mechanics energies combined with the generalized Born and surface area 
continuum solvation 
 
 at U
N
IV
ERSITY
 O
F D
U
N
D
EE on M
ay 3, 2018
http://w
w
w
.jbc.org/
D
ow
nloaded from
 
Druggable rhoA/Net1 interface 
21 
 
Figure 11: Biochemical characterization of the inhibitory effect of peptides on the 
Net1/RhoA GTP/GDP exchange reaction 
(A) Schematic representation of the inhibitor peptides. The peptide names (left) include 
number ranges that correspond to the amino acid sequences (right). (B) Inhibition of Net1-
mediated RhoA GTP/GDP exchange with different inhibitor peptides (all at 0.5 mM). 
Symbols (from top to bottom): closed circles: no peptide, open circles: peptide 100-105, 
upward triangles: peptide 100-109, stars: peptide 96-102, large upward triangles: peptide 96-
106, downward triangles: peptide 101-106, diamonds: peptide 102-106 and squares: peptide 
100-106. (C) Inhibition of Net1-mediated RhoA GTP/GDP exchange with different 
concentrations of peptide 102-106: Symbols from top to bottom: circles: no peptides 
(control), stars: 0.03 mM, diamonds: 0.0625 mM, downward triangles: 0.125 mM, upward 
triangles: 0.35 mM and squares: 0.5 mM. The experiments were run at least 3 times, 
independently. A representative curve is presented here. 
 
Figure 12: Biochemical characterization of GTP/GDP exchange activities for 
GEF3/RhoA, and GEF12/RhoA complexes 
 (A) GEF3-mediated RhoA GTP/GDP exchange reaction is not inhibited by 0.5 mM inhibitor 
peptide 102-106. RhoA exchange activity was measured in the presence of GEF3 (10 µM, 
dark triangles) or in the presence of both GEF3 (10 µM) and peptide 102-106 (0.5 mM, open 
triangles). (B) GEF12-mediated RhoA GTP/GDP exchange reaction is not inhibited by 0.5 
mM inhibitor peptide 102-106. RhoA exchange activity was measured in the presence of 
GEF12 (0.05 µM, dark squares) or in the presence of both GEF12 (0.05 µM) and peptide 102-
106 (0.5 mM, open squares). The experiments were run at least 3 times, independently. A 
representative curve is presented here. 
 
Figure 13: Sequence alignment of Net1, GEF3, and GEF12. 
Amino acid sequences of Net1
PH
, GEF3, and GEF12 were aligned with the EMBL-EBI 
Clustal Omega. Secondary structure attributions for Net1
PH
 (PDB: 4XH9; indicated above the 
corresponding sequences) were identified with the DSSP program. Residues involved in the 
Net1
PH
/RhoA formation are enclosed in boxes. 
 
Figure 14: Further biochemical characterization of the peptide 102-106 inhibition of the 
GTP/GDP exchange activities for mutated Net1/RhoA, and  GEF3/RhoA.  
 
(A) The Net1-mediated RhoA GTP/GDP exchange reaction is measured in the presence (open 
symbols) or not (dark symbols) of 0.5 mM of the peptide 102-106. Mutated Net1 (H488N – 
diamonds - or H488A -circles) were used in those assay together with RhoA. (B) The 
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GEF3(N436H) mutant-mediated RhoA GTP/GDP exchange reaction is measured in the 
presence (open symbols) or not (dark symbols) of 0.5 mM of the peptide 102-106.  The 
experiments were run at least 3 times, independently. A representative curve is presented 
here. 
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Figure 1 
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Figure 2. 
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Figure 3. 
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Figure 4. 
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Figure 5. 
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Figure 6. 
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Figure 7. 
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Figure 8. 
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Figure 9. 
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Figure 10. 
 
 
 
 at U
N
IV
ERSITY
 O
F D
U
N
D
EE on M
ay 3, 2018
http://w
w
w
.jbc.org/
D
ow
nloaded from
 
Druggable rhoA/Net1 interface 
33 
 
 
 
Figure 11. 
 
 at U
N
IV
ERSITY
 O
F D
U
N
D
EE on M
ay 3, 2018
http://w
w
w
.jbc.org/
D
ow
nloaded from
 
Druggable rhoA/Net1 interface 
34 
 
Figure 12. 
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Figure 13. 
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Figure 14. 
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